Longboard Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Longboard Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2024.
  • Longboard Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$24.5M, a 89.7% decline year-over-year.
  • Longboard Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$76.3M, a 50.5% decline year-over-year.
  • Longboard Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$54.4M, a 23.8% decline from 2022.
  • Longboard Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$43.9M, a 58.1% decline from 2021.
  • Longboard Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$27.8M, a 93% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$76.3M -$24.5M -$11.6M -89.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$64.7M -$21.8M -$6.79M -45.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$58M -$15M -$3.53M -30.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 -$54.4M -$15M -$3.69M -32.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-12
Q3 2023 -$50.7M -$12.9M -$1.34M -11.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$49.4M -$15M -$3.59M -31.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$45.8M -$11.5M -$1.86M -19.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$43.9M -$11.3M -$2.57M -29.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-12
Q3 2022 -$41.4M -$11.6M -$5.25M -82.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$36.1M -$11.4M -$4.43M -63.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-02
Q1 2022 -$31.7M -$9.6M -$3.9M -68.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-02
Q4 2021 -$27.8M -$8.77M +$1.34M +13.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-02
Q3 2021 -$29.1M -$6.35M -$3.8M -149% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$25.3M -$6.98M -$5.41M -345% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$19.9M -$5.7M -$5.53M -3175% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$14.4M -$10.1M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-03
Q3 2020 -$2.55M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$1.57M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$174K Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.